About the Non Hodgkin Lymphoma Session
Non-Hodgkin lymphoma (NHL) represents a diverse group of blood cancers originating from lymphocytes, a type of white blood cell. In cancer research, understanding the heterogeneity of NHL is pivotal. Researchers delve into the molecular and genetic underpinnings of NHL subtypes, aiming for tailored treatments. Immunotherapy, targeted therapies, and precision medicine are revolutionizing NHL management, offering more effective and less toxic options. Clinical trials explore novel approaches, including CAR-T cell therapy and immune checkpoint inhibitors, to enhance patient outcomes. Moreover, advancements in biomarker identification and diagnostic techniques promise earlier detection and personalized treatment strategies. Collaborative efforts among researchers globally continue to drive progress in unraveling NHL complexities, bringing hope for improved survival rates and quality of life for patients.
Topics Covered in Non Hodgkin Lymphoma
Large B-Cell Lymphoma
Follicular Lymphoma
T-Cell Lymphomas
Molecular Subtyping
CAR-T Therapy
Bispecific Antibodies
Related Scientific Sessions at CIOC 2027
Why Attend the Non Hodgkin Lymphoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Non Hodgkin Lymphoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Non Hodgkin Lymphoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Non Hodgkin Lymphoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Non Hodgkin Lymphoma Conference 2027 — FAQs
What is the Non Hodgkin Lymphoma track at CIOC 2027?
The Non Hodgkin Lymphoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Non Hodgkin Lymphoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Non Hodgkin Lymphoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Non Hodgkin Lymphoma are all welcome — whether presenting or attending.
Can I present my research in the Non Hodgkin Lymphoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Non Hodgkin Lymphoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Non Hodgkin Lymphoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.